1-3 of 3
Nelson Guerreiro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study

Albiruni R. Abdul Razak, Sebastian Bauer, Cristina Suarez, Chia-Chi Lin, Richard Quek, Marie Luise Hütter-Krönke, Ricardo Cubedo, Stephane Ferretti, Nelson Guerreiro, Astrid Jullion, Elena J. Orlando, Giorgia Clementi, Janna Sand Dejmek, Ensar Halilovic, Claire Fabre, Jean-Yves Blay, Antoine Italiano
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1087–1097.
https://doi.org/10.1158/1078-0432.CCR-21-1291
Published: 14 March 2022
View article titled, Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Open the PDF for Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Eytan M. Stein, Daniel J. DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Chia-Chi Lin, Cristina Suarez, Filip de Vos, Neeltje Steeghs, Philippe A. Cassier, David Tai, Jean-Jacques Kiladjian, Noboru Yamamoto, Rogier Mous, Jordi Esteve, Hironobu Minami, Stephane Ferretti, Nelson Guerreiro, Christophe Meille, Rajkumar Radhakrishnan, Bernard Pereira, Luisa Mariconti, Ensar Halilovic, Claire Fabre, Cecilia Carpio
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 870–881.
https://doi.org/10.1158/1078-0432.CCR-21-1295
Published: 01 March 2022
View article titled, Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <em>TP53</em> Solid Tumors and Acute Leukemia
Open the PDF for Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <em>TP53</em> Solid Tumors and Acute Leukemia in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung-Bae Kim, Ava Kwong, Guenther G. Steger, Esther Zamora Adelantado, Francois P. Duhoux, Richard Greil, Irene Kuter, Yen-Shen Lu, Ariadna Tibau, Mustafa Özgüroğlu, Christian W. Scholz, Christian F. Singer, Estela Vega, Pauline Wimberger, Claudio Zamagni, Xuan-Mai Couillebault, Liqiong Fan, Nelson Guerreiro, Jennifer Mataraza, Janna Sand-Dejmek, Arlene Chan
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 106–115.
https://doi.org/10.1158/1078-0432.CCR-20-3955
Published: 05 January 2022
View article titled, A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Open the PDF for A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer in another window
Includes: Supplementary data